Ayvens : The beginning of the move
Entry price | Target | Stop-loss | Potential |
---|
€16.05 |
€18.3 |
€14.85 |
+14.02% |
---|
A strong break-out to the upside has recently been seen in ALD. The current technical chart pattern could allow for a continuation of the upward dynamic.
Strengths● Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
● The company's attractive earnings multiples are brought to light by a P/E ratio at 11 for the current year.
● This company will be of major interest to investors in search of a high dividend stock.
● Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
● The tendency within the weekly time frame is positive above the technical support level at 13.83 EUR
Weaknesses● The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.